Beam Therapeutics 1 article

The defining editing modality for Beam Therapeutics is base editing; adenine base editing supplies the molecular or delivery context that makes the platform distinctive. The company also draws on cytosine base editing and genome editing without double-strand breaks; ex vivo hematopoietic stem cell editing supplies the application context for the intended genomic change. GenoMethods separates genome-editing methods from the corporate entity and from individual genetic medicines; the editing profile of Beam Therapeutics also includes sickle cell genetic medicine.